Machine learning and microbes: How big data is redefining biotechnology

Machine learning and artificial intelligence are all the rage today in venture capital circles. We’ve seen spectacular exits in the past few years, from Google absorbing Deepmind in 2014 for $500 million, to Twitter buying TellApart in 2015 for $533 million, and Intel swallowing Nervana in 2016 for $400 million. But these were all IT plays.

What happens when machine learning meets biology? Berkeley-based Lygos is engineering and designing microbes that convert low-cost sugar into high-value, specialty chemicals. At the core, they’re developing and exploiting a number of tools, both software and hardware, and applying them to biology.

Author: Matt Asay


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s